
    
      Part 1 is the open label, dose-escalation phase Ib portion of the study to establish the
      maximum tolerated dose (MTD)/RP2D of APG-115 in combination with pembrolizumab. Four dose
      levels of APG-115 will be administered: 50mg, 100mg, 150mg, and 200mg. APG-115 will be
      administered orally every other day (QOD) for consecutive 2 weeks and 1 week off dosing as a
      cycle of 21 days (3 weeks), pembrolizumab will administrated with label dose.

      Part 2 is a phase II study design, includes cohort A-F five arms. The patients will be
      treated with APG-115 at 150 mg QOD (RP2D) in combination with pembrolizumab until disease
      progression, unacceptable toxicity, or another discontinuation criterion is met.
    
  